Related Experiment Videos
Abciximab and percutaneous coronary intervention: new indications. Medium-term benefit
Insights
Abciximab effectively prevents ischemic complications and myocardial infarction in patients undergoing percutaneous coronary intervention and those with unstable angina. Bleeding risks were manageable with adjusted heparin doses and site precautions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Abciximab is indicated for preventing ischemic complications in percutaneous coronary intervention (PCI) and myocardial infarction in unstable angina patients undergoing PCI.
- Clinical data for abciximab now includes three placebo-controlled trials.
Purpose of the Study:
- To evaluate the efficacy and safety of abciximab in patients undergoing percutaneous coronary intervention and those with unstable angina.
Main Methods:
- Analysis of three placebo-controlled trials: EPIC (high-risk thrombosis patients), EPILOG (all risk levels), and CAPTURE (unstable angina patients).
- Assessment of overall mortality, myocardial infarction risk, and bleeding events.
Main Results:
- Abciximab did not reduce overall mortality in either EPIC or EPILOG trials.
- In high-risk patients, abciximab reduced new myocardial infarction risk at one year, but not long-term.
- In lower-risk patients, the reduction in reinfarction risk persisted for at least six months.
- The CAPTURE trial showed abciximab, initiated 24 hours pre-angioplasty for unstable angina, reduced one-month myocardial infarction risk.
- Bleeding risk was controlled with weight-adjusted heparin and strict injection site precautions.
Conclusions:
- Abciximab demonstrates efficacy in preventing ischemic complications and myocardial infarction in specific patient populations undergoing PCI and those with unstable angina.
- Careful management of heparin dosage and injection site protocols effectively controls bleeding risk associated with abciximab therapy.
Abstract:
(1) Abciximab is now indicated for the prevention of ischaemic complications in patients undergoing percutaneous coronary intervention, and for the prevention of myocardial infarction in patients with unstable angina undergoing percutaneous coronary intervention. (2) The clinical file on abciximab now includes three placebo-controlled trials. (3) The EPIC trial involved patients at high risk of thrombosis, while the EPILOG trial included patients regardless of their risk of thrombosis. In neither trial did abciximab reduce overall mortality. In high-risk patients abciximab reduced the risk of a new myocardial infarction at one year, but not for longer. In patients at lower risk, the reduction in the risk of reinfarction persisted for at least six months. (4) The CAPTURE trial showed that abciximab, started 24 hours before angioplasty for unstable angina, reduced the risk of myocardial infarction at one month. (5) The bleeding risk was controlled by the use of heparin at doses adjusted to body weight, and by applying strict precautions to protect the injection site.